Literature DB >> 16443419

Pulmonary embolism as a cause of death in patients who died with cancer.

Paul D Stein1, Afzal Beemath, Frederick A Meyers, Fadi Kayali, Elias Skaf, Ronald E Olson.   

Abstract

Little is known about the frequency of death from pulmonary embolism in patients who die with cancer. We investigated this on the basis of data from death certificates, as listed by the United States Bureau of the Census in the period 1980-1998. Among patients with cancer who died over the 19-year period of study, pulmonary embolism was the listed cause of death in 0.21% (95% confidence interval, [CI] 0.21-0.22%). The frequency of death from pulmonary embolism in patients who died with cancer decreased from 0.39% in 1980 to 0.15% in 1998. Adjustment of the data for the frailty of the diagnosis of fatal pulmonary embolism based on death certificates indicated a likely range of 0.60% to 1.05% for the frequency of death from pulmonary embolism among patients who died with cancer in the period 1980-1998. In conclusion, with modern diagnostic, prophylactic, and therapeutic methods, death from pulmonary embolism in patients who died with cancer was 1% or less.

Entities:  

Mesh:

Year:  2006        PMID: 16443419     DOI: 10.1016/j.amjmed.2005.02.028

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  7 in total

1.  Opioid growth factor improves clinical benefit and survival in patients with advanced pancreatic cancer.

Authors:  Jill P Smith; Sandra I Bingaman; David T Mauger; Harold H Harvey; Laurence M Demers; Ian S Zagon
Journal:  Open Access J Clin Trials       Date:  2010-03-01

2.  Preventing Venous Thromboembolism in Ambulatory Cancer Patients: The ONKOTEV Study.

Authors:  Chiara Alessandra Cella; Giovanni Di Minno; Chiara Carlomagno; Michele Arcopinto; Anna Maria Cerbone; Elide Matano; Antonella Tufano; Florian Lordick; Biagio De Simone; Katja Sibylle Muehlberg; Dario Bruzzese; Laura Attademo; Claudia Arturo; Marta Sodano; Roberto Moretto; Ersilia La Fata; Sabino De Placido
Journal:  Oncologist       Date:  2017-04-19

3.  Thromboprophylaxis for patients with newly diagnosed vs. recurrent cancers: a post-hoc analysis of the avert trial.

Authors:  James Zhang; Marina Atalla; Ranjeeta Mallick; Philip S Wells; Marc Carrier
Journal:  J Thromb Thrombolysis       Date:  2020-10-20       Impact factor: 2.300

4.  In-hospital prognosis of malignancy-related pulmonary embolism: an analysis of the national inpatient sample 2016-2018.

Authors:  Dae Yong Park; Seokyung An; Ibrahim Kashoor; Olisa Ezegwu; Shweta Gupta
Journal:  J Thromb Thrombolysis       Date:  2022-07-25       Impact factor: 5.221

5.  Risk of Thrombosis in Adult Philadelphia-Positive ALL Treated with an Asparaginase-Free ALL Regimen.

Authors:  Ruiqi Chen; Xing Liu; Arjun D Law; Solaf Kanfar; Dawn Maze; Steven M Chan; Vikas Gupta; Karen W Yee; Mark D Minden; Aaron D Schimmer; Andre C Schuh; Caroline J McNamara; Tracy Murphy; Anna Xu; Umberto Falcone; Jack Seki; Hassan Sibai
Journal:  Curr Oncol       Date:  2020-12-22       Impact factor: 3.677

6.  Correlates of in-hospital deaths among hospitalizations with pulmonary embolism: findings from the 2001-2008 National Hospital Discharge Survey.

Authors:  James Tsai; Scott D Grosse; Althea M Grant; Nimia L Reyes; W Craig Hooper; Hani K Atrash
Journal:  PLoS One       Date:  2012-07-06       Impact factor: 3.240

7.  A retrospective study of venous thromboembolism in acute leukemia patients treated at the University of Texas MD Anderson Cancer Center.

Authors:  Khanh Vu; Nhiem V Luong; Julie Hubbard; Ali Zalpour; Stefan Faderl; Deborah A Thomas; Daisy Yang; Hagop Kantarjian; Michael H Kroll
Journal:  Cancer Med       Date:  2014-12-08       Impact factor: 4.452

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.